

Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients

NCT07195032

| | |
|-------------------|---------------------------------------|
| Status | RECRUITING |
| Phase | Phase 4 |
| Sponsor | Children's Mercy Hospital Kansas City |
| Enrollment | 60 participants |

Key Eligibility Criteria

Inclusion (7)

- Received a heart transplant
- At least 1 year after transplant
- At least 1 year after antibody-mediated rejection treatment (intravenous immune globulin, rituximab, bortezomib, plasmapheresis, carfilzomib, eculizumab, daratumumab)
- At least 1 year from anti-thymocyte globulin
- At least 6 months after pulse dose steroid treatment or basiliximab treatment
- ... and 2 more (see full listing online)

Exclusion (2)

- History of repeated infections necessitating adjustment in immunosuppression to non-standard regimen, including single agent immunosuppression and modified trough levels.
- History of anaphylactic reaction to MMR vaccination

Locations (1 total)

Children's Mercy Hospital, Kansas City, Missouri, United States